City Therapeutics to Present at Upcoming November Investor Conferences
Previous
Previous
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
Next
Next